TransCode Therapeutics (RNAZ) Proxy Filing summary

Executive summary

• Entered into a definitive agreement to acquire 100% of Polynoma, expanding the pipeline with a Phase 3-ready melanoma vaccine and securing a $25 million strategic investment from CK Life Sciences, with up to $95 million in milestone payments possible.

• The acquisition and investment are structured through the issuance of common and preferred stock, with conversion subject to shareholder approval, and include a non-transferable contingent value right (CVR) for existing shareholders tied to future asset monetization.

• Board unanimously approved the transactions, which are not subject to prior shareholder approval but require a future vote for conversion of preferred shares and change of control under Nasdaq rules.

• A registration rights agreement ensures resale registration for shares issued in the transaction, and a repurchase agreement gives the seller an option to reacquire the acquired entity under certain conditions.

Voting matters and shareholder proposals

• Shareholders will be asked to approve the conversion of Series A Preferred Stock to common stock and a change of control under Nasdaq rules at a future meeting.

• A proxy statement will be filed within 30 days of receiving required financial statements, and the board will recommend approval.

Board of directors and corporate governance

• Elizabeth Czerepak appointed as independent director and Audit Committee chair, bringing extensive biotech and financial experience.

• Board composition will expand to include a seller-nominated director, with further changes post-shareholder approval.

• CEO transition: Philippe Calais appointed CEO, Tom Fitzgerald returns to CFO role, both receiving one-time transaction bonuses.